← Compound Library

Exenatide

GLP-1 Receptor Agonist

Also known as: Byetta · Bydureon · Exendin-4

The first GLP-1 receptor agonist approved for clinical use, derived from the Gila monster venom peptide Exendin-4. Available in twice-daily & once-weekly formulations.

Typical Dose

5–10 mcg 2x/day (IR); 2 mg/week (ER)

Route

Subcutaneous injection

Cycle

Continuous

Half-life

~2.4 hours (IR); release-controlled for ER formulation

Storage

2–8°C. IR pen: room temp up to 30 days after first use.

Overview

Exenatide (Exendin-4) is a 39-amino-acid peptide originally isolated from Heloderma suspectum (Gila monster) saliva with 53% homology to human GLP-1 but resistance to DPP-4 degradation. It was the first GLP-1 agonist to reach clinical use (Byetta, 2005) & was the foundational compound validating the GLP-1 receptor as a therapeutic target.

It has largely been superseded by longer-acting GLP-1 agonists (liraglutide, semaglutide) in clinical practice, but remains used in research & as a reference compound. In research peptide form it is used identically to other GLP-1 agonists.

Quick Start Guide

1

Immediate-release: inject 5 mcg SubQ twice daily (within 60 min before morning & evening meals). Escalate to 10 mcg 2x/day after 4 weeks.

2

Extended-release (Bydureon): 2 mg SubQ once weekly.

Research Indications

Type 2 diabetes

Most Effective

FDA approved; reduces HbA1c by ~0.8–1.5%. Weight-neutral to modest weight loss effect.

Weight loss (modest)

Moderate

Produces 2–3 kg weight loss versus placebo; less than liraglutide or semaglutide.

Research Protocols

Glycemic control

Continuous

Dose

5 mcg 2x/day → 10 mcg 2x/day

Frequency

Twice daily, before meals

Route

SubQ abdomen/thigh

Peptide Interactions

Do not combine GLP-1 agonists.

Side Effects & Safety

Common

  • Nausea
  • Vomiting
  • Diarrhea
  • Hypoglycemia (with sulfonylurea)

Uncommon

  • Pancreatitis
  • Injection site nodules (ER formulation)
  • Renal impairment (rare)

When to Stop

  • Severe renal impairment (GFR < 30)
  • Suspected pancreatitis
  • Signs of allergic reaction

How to Reconstitute

1

Wipe vial stopper.

2

Inject bacteriostatic water down inner wall. Swirl.

3

Refrigerate. Use within 28 days.

Dosing math: Typical compounded concentration: 1 mg/mL. For 5 mcg dose: 0.005 mL — usually prepared at higher concentration (e.g., 0.5 mg/mL for 5 mcg = 0.01 mL).

Quality Indicators

Good — use as normal

  • Clear, colorless solution

Acceptable

  • Very faint tint

Discard immediately

  • Cloudiness
  • Particulate

What to Expect

Week 1–4

Nausea peaks. Appetite reduction begins.

Weeks 5–12

Modest weight loss & glycemic improvement.

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Research References

Exenatide effects on diabetes, obesity, cardiovascular risk factors & hepatic biomarkers in patients with type 2 diabetes

Diabetes Care · 2005

First large clinical validation of Exendin-4 (Exenatide) for T2D; foundational GLP-1 receptor agonist trial.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-TOF-MS & HPLC analysis with a signed analytical report.

Submit a sample